anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic graft-versus-host-disease (cGVHD) is one of the primary causes of morbidity and mortality for patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HCT). In recent years, advancements in allo-HCT have allowed a broader range of patients to receive transplant, particularly older patients. We sought to assess the impact of cGVHD on outcomes in patients undergoing allo-HCT, for older patients as compared to their counterparts. We performed a retrospective analysis of all patients who underwent allo-HCT 1999-2018. Our results showed that those patients who developed cGVHD by D + 180 had an increased risk and incidence of NRM as compared to those patients without cGVHD. There was no significant difference in outcomes for those patients with cGVHD by age (≥60 years old [yo] and <60 yo). These findings suggest the significant morbidity of cGVHD, regardless of age.
Participants will receive bortezomib, lenalidomide, and dexamethasone (VRd) regimen for 6 cycles before randomization. Following randomization, participants in Arm A will receive 2 more cycles of VRd. In VRd treatment, participants will receive bortezomib 1.3 milligram per meter square (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each cycle (Cycles 1 to 8), oral lenalidomide 25 mg on Days 1 to 14 of each cycle (Cycles 1 to 8) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle (Cycles 1 to 8). Each cycle will consist of 21 days. After 8 cycles of VRd, treatment will continue with lenalidomide and dexamethasone (Rd) maintenance therapy. In Rd treatment, participants will receive oral lenalidomide 25 mg on Days 1 to 21 of each cycle and oral dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle. Each cycle will consist of 28 days. Participants will continue to receive Rd until confirmed progressive disease or unacceptable toxicity.
INTRODUCTION: Paediatric CSF shunt infection rate remains a well-known complication that is not only responsible of potentially severe sequels for patients but also for economical expenses. In that study, we questioned if it is possible to attain the zero percent rate of infection that should be the goal of every paediatric neurosurgeon.
METHODS: We report our series of patients treated with a CSF device from January the first 2016 to December 31 2018.
RESULTS: In all 147 patients treated for hydrocephalus, the follow-up was of at least of 2 years from the implantation. Antibiotic-coated tubes were always used with a differential pressure valve system. A total of 172 surgical procedures were performed for 147 patients. In the follow-up time period, 4 patients presented a post-operative infection (2.3%). Two infections appeared early after the surgical procedure one after 24 h and the other after 6 days; the other two infections were diagnosed after 53 days and the other after 66 days. The germs responsible of the infections were a Staphylococcus capitals, an Escherichia coli, a Klebsiella pneumonia, and a Staphylococcus aureus.
CONCLUSIONS: Shunts will always be implanted especially in new-borns and for particular aetiologies of hydrocephalus. To reduce the rate of infection, the best thing to do is to adopt adapted protocols. Our low incidence of infection rate for shunts represent a long history to research preventive factors that helped us to improve our results during the time.
PURPOSE:A prolonged release type cefadroxil pharmaceutical, prepared by incorporating a cefadroxil pharmaceutical disintegrable in the stomach with an enteric cefadroxil pharmaceutical, having prolonged action on blood concentration without delay in the initial concentration by the oral administration, and useful as an antimicrobial agent. CONSTITUTION:A prolonged release type pharmaceutical prepared by incorporating (A) a cefadroxil pharmaceutical disintegrable in the stomach with (B) an enteric cefadroxil pharmaceutical. The mixing potency ratio is preferably (30- 50):(70-50). The cefadroxil pharmaceutical disintegrable in the stomach (A) is preferably fine particles or granules disintegrable in the stomach, and the enteric cefadroxil pharmaceutical (B) is perferably fine particles or granules obtained by coating the pharmaceutical disintegralbe in the stomach (A) with an enteric film substance, e.g. ''Eudragit'' or carboxymethyl ethyl cellulose. The resultant pharmaceutical maintains the blood concentration at the time of administration for a long time without delay in the initial concentration.
Subjects participated in four sessions (20 min/session) of mindfulness training. Participants were taught that perceived sensory events are "momentary" and "fleeting" and require no further evaluation. They were asked to close their eyes, relax and to focus on the flow of their breathing and "simply let go" of discursive thoughts.
Patients will receive neoadjuvant chemotherapy for 4 months. Patients will undergo a CT scan at 8 weeks and 16 weeks after the start of neoadjuvant chemotherapy to assess treatment response. Patients without disease progression will then undergo AD-XRT for 15 to 25 fractions (3 to 5 weeks). Patient's whose disease is deemed resectable based on their re-evaluating imaging, will be recommended surgical intervention with consideration for laparotomy or laparoscopy if deemed appropriate at multidiscplinary cancer conference review.
PURPOSE:An anti-cancer drug containing fresh water chlorella as a main component. CONSTITUTION:Fresh water Chlorella (e.g., Chlorella pyrenoidosa, Chlorella vulgaris, Chlorella ellipsoidea, etc.,) is obtained by culture containing 0.1-800ppm iodine ion and/or iodic acid at pH 4-7 in the presence of light rays. After the culture is over, Chlorella is separated from water by centrifugal separation, simultaneously washed with water to tive Chlorella with low water content. The Chlorella is successively dried by spray dry lyophilization, etc. Drying is important with regard to prevention of change in quality of Chlorella. An anti-cancer drug containing the prepared fresh water Chlorella as a main component is obtained.
The present disclosure generally relates to compositions comprising dihexa and methods for making or using said compositions. In some aspects, the compositions disclosed herein may comprise one or more additional active ingredients, including lipoic acid, spadin peptide, and/or phenyl-N-tert-butylnitrone. Compositions such as these may be used in certain embodiments, for example, to enhances a subject's hearing or to treat a hearing disorder, etc. In some embodiments, the compositions are topical compositions configured to treat hearing loss via administration, e.g., to the skin behind the outer ear or directly to the eardrum of a subject, etc. In some cases, the compositions disclosed herein may comprise one or more excipients to aid in transdermal delivery. For instance, in certain embodiments, the compositions comprise lecithin and/or other components that may facilitate delivery through the skin. Other aspects are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
Participants in the intervention group engaged in bingo, matching pairs, word challenges, and hot-and-cold games, organized into groups of eight individuals. They adhered to the game instructions and participated in sessions twice a week for 2 months, totalling 16 sessions. In each session, all individuals played all four games, so one played 64 games in 16 sessions. Sessions are planned to last 45 minutes.
1. Extract must be stored at 2°C to 8°C to retain potency. Storage at this temperature should be observed as closely as possible, since higher temperatures adversely affect the antigen E content of the product. Extract should not be left at room temperature for the purpose of making dilutions or mixing with other allergenic materials, unless precautions are taken to maintain the recommended temperature using special cooling trays or other suitable methods.
  2. Extract should be administered with autoclaved or sterile disposable syringes, needles and testing devices to prevent the transmission of homologous serum hepatitis and other infectious agents from person to person.
  3. Extract may cause local or generalized reactions. Physicians who administer the product should be familiar with the principles and practice of allergy and should have epinephrine HCL 1:1,000, as well as other emergency medication and equipment available to treat anaphylaxis. Persons receiving extract by skin test or by subcutaneous injection for treatment must be instructed to remain in the physician's office for 20 minutes following testing or immunotherapy, and to return immediately to the office if any signs of a generalized allergic reaction occur, including hives, symptoms of hay fever, and/ or asthma.
  4. PREGNANCY CATEGORY C. ragweed pollen extract. Animal reproduction studies have not been conducted with ragweed pollen extract. It is also not known whether ragweed pollen extract can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ragweed pollen extract should be given to a pregnant woman only if clearly needed.
The invention provides an osteogenic differentiation inducer, which is characterized in that the osteogenic differentiation inducer is puerarin. The puerarin can promote differentiation from marrow mesenchymal stem cells into osteogenesis by regulation and control of ERK1/2 signal pathway in vitro. Puerarin can induce osteogenic differentiation of marrow mesenchymal stem cells for controlling osteoporosis by regulation and control of ERK1/2 signal pathway. Marrow mesenchymal stem cells can be applied to seed cells in bone tissue engineering and cell transplantation. Medicament prepared from puerarin for treating bone disease combines with marrow mesenchymal stem cell transplantation can be used for controlling bone disease. The effect of plant estrogen of puerarin in the aspect of osteoporosis control can replace that of the estrogen therapy, thereby avoiding adverse reaction caused by long-term application of estrogen. Medicament prepared from puerarin for treating bone disease combines with marrow mesenchymal stem cell transplantation can be used for controlling some bone diseases.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to formulas of new drugs and methods of treatment of bacterial and viral infections. Curative-prophylactic preparation in solid and soft forms has a base, bacterial mass of alive bacteria-eubiotics and biologically active components showing immunomodulating, regenerative and protective effect being the latter are the following agents: lysozyme or alpha-2-interferon, or hyaluronic acid, or lysozyme and hyaluronic acid, or alpha-2-interferon and hyaluronic acid. Preparation has additionally vitamins E and C. Dried bacterial mass of the strain of Bifidobacterium bifidum N 791 or LBA-3, or the strain Lactobacillus acidophilus 317/402 or the mixture of indicated strains at ratio 1:1 at the total amount 1 x 10 7  CFU per a dose, not less, or strains Lactobacillus acidophilus 100 H, Lactobacillus acidophilus NK 1 , Lactobacillus acidophilus K 3 Ш 24  at ratio 1:1:1 at the total amount 1 x 10 7  CFU per a dose, not less, at the following ratio of components in drug, mg: dried bacterial mass of bacteria-eubiotics, 10.0-100.0; biologically active components, 0.01-100.0; vitamin E, 6.0-10.0; vitamin C, 1.0-2.0; base, up to 2000 mg. Treatment with proposed preparation is carried out by its simultaneous oral, intravaginal and/or rectal routes of administration. EFFECT: improved method of treatment and prophylaxis, enhanced effectiveness of preparation. 7 cl, 18 ex
Conduct a RCT pilot of the modified B-SWELL consisting of 64 women randomized to B-SWELL (n=32) or control (n=32). The RCT will take place in two phases. Each phase will consist of virtual and in-person groups (n=8 for groups) for the B-SWELL and attention control. Participants will receive the B-SWELL materials (binder, flash drive) prior to start. Each weekly 90-minute session is devoted to a specific LE8 behavior. Sessions will begin with meditative practice followed by interactive presentations, review of case studies, and discussion. Coaching will occur via phone during the first weeks of the intervention with booster sessions at weeks 10 and 14. The attention control (virtual or in person) will mirror the B-SWELL in format and duration however, participants will only receive publicly available AHA materials and information. The Attention control will not receive stress information, goal setting, or coaching. Facilitators and coaches will be purposefully recruited and representative of midlife Black women.

This study will take place in Cincinnati. Women will be eligible if they identify as Black/African American; are between the ages of 45 and 64 during the trial; have a reliable phone for messaging and data collection calls; and willing to commit to the study duration and data collection phone calls (at 8, 12 and 16 weeks). Women will be excluded if they have recently immigrated or resettled in the U.S. or have major health conditions prohibiting safe participation. Having CVD will not be an exclusion as those with CVD can still show improvement in LE8. Recruitment activities will include fliers, email, snowballing, and social media. Community in-person sites will be selected based upon safety, accessibility, and resources. The C-RAB members will inform recruitment through their knowledge of the communities. For example, they may recommend that fliers be placed in particular high-traffic areas or sent to specific community organizations. C-RAB members are not personnel and, thus, will be instructed to refer any questions regarding this research to the PI and/or research staff. All C-RAB activities will be monitored by the PI.
Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. 

The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD [see Clinical Studies (14)].

A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Types requires both inattentive and hyperactive-impulsive criteria to be met.

Special Diagnostic Considerations

Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics. 

Need for Comprehensive Treatment Program

Focalin XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms.

Long-Term Use

The effectiveness of Focalin XR for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Focalin XR for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.3)].
This study aimed to investigate the protective effects of ginsenoside Rg1 on high-altitude hypoxia-induced acute lung injury (ALI) and elucidated its molecular targets and related pathways, specifically its association with the fluid shear stress pathway. Using a combination of bioinformatics analysis and both in vivo and in vitro experiments, we assessed the role of ginsenoside Rg1 in mitigating physiological and biochemical disturbances induced by hypoxia. In the in vivo experiments, we measured arterial blood gas parameters, levels of inflammatory cells and cytokines, erythrocyte and platelet parameters, and conducted histological analysis in rats. The in vitro experiments utilized human pulmonary microvascular endothelial cells (HPMECs) and A549 cells to examine cell viability, intracellular reactive oxygen species (ROS) and Ca2⁺ levels, and mitochondrial function. The results of the in vivo experiments demonstrate that ginsenoside Rg1 significantly increased arterial blood oxygen partial pressure and saturation, elevated arterial blood glucose levels, and stabilized respiratory and metabolic functions in rats. It also reduced inflammatory cells and cytokines, such as tumor necrosis factor-α and interleukin-6, and improved erythrocyte and platelet abnormalities, supporting its protective role through the regulation of the fluid shear stress pathway. Histological and ultrastructural analyses revealed that Rg1 significantly protected lung tissue structure and organelles. In vitro experiments further confirmed that Rg1 improved cell viability in HPMEC and A549 cells under hypoxic conditions, decreased intracellular ROS and Ca2⁺ levels, and enhanced mitochondrial function. These findings collectively demonstrate that ginsenoside Rg1 exerts significant protective effects against high-altitude hypoxia-induced ALI by enhancing oxygen delivery and utilization, reducing inflammatory responses, and maintaining cellular metabolism and vascular function. Notably, the protective effects of Rg1 are closely associated with the regulation of the fluid shear stress pathway, suggesting its potential for treating high-altitude hypoxia-related diseases.
AIM: Sodium glucose co-transporter-2 (SGLT2) inhibitors stimulate renal excretion of sodium and glucose and exert renal protective effects in patients with (non-)diabetic chronic kidney disease (CKD) and may as well protect against acute kidney injury (AKI). The mechanism behind this kidney protective effect remains unclear. Juxtaglomerular cells of renin lineage (CoRL) have been demonstrated to function as progenitors for multiple adult glomerular cell types in kidney disease. This study assesses the impact of SGLT2 inhibition on the repopulation of glomerular cells by CoRL and examines their phenotypic commitment.
METHODS: Experiments were performed in Ren1cre-tdTomato lineage-trace mice. Either 5/6 nephrectomy (5/6NX) modeling CKD or bilateral ischaemia reperfusion injury (bIRI) mimicking AKI was applied, while the SGLT2 inhibitor empagliflozin (10 mg/kg) was administered daily via oral gavage for 14 days.
RESULTS: Both 5/6NX and bIRI-induced kidney injury increased the number of glomerular CoRL-derived cells. SGLT2 inhibition improved kidney function after 5/6NX, indicated by decreased blood creatinine and urea levels, but not after bIRI. In line with this, empagliflozin in 5/6NX animals resulted in less glomerulosclerosis, while it did not affect histopathological features in bIRI. Treatment with empagliflozin resulted in an increase in the number of CoRL-derived glomerular cells in both 5/6NX and bIRI conditions. Interestingly, SGLT2 inhibition led to more CoRL-derived podocytes in 5/6NX animals, whereas empagliflozin-treated bIRI mice presented with increased levels of parietal epithelial and mesangial cells derived from CoRL.
CONCLUSION: We conclude that SGLT2 inhibition by empagliflozin promotes CoRL-mediated glomerular repopulation with selective CoRL-derived cell types depending on the type of experimental kidney injury. These findings suggest a previously unidentified mechanism that could contribute to the renoprotective effect of SGLT2 inhibitors.
Context: Adipose-derived mesenchymal stem cells (ADMSCs) are progenitor cells that shape the tissue's biological properties. Objective: To examine the adipocytes differentiated from the ADMSCs of lean and obese individuals with/without a metabolic syndrome (MetSx) cytokine secretory profile, as to date, little is known on this topic. Methods: Interleukin, chemokine and growth factor levels in the culture medium were determined using the Human Cytokine kit. Results: We observed a characteristic secretory fingerprint displayed by the cells from the MetSx group and identified a set of putative markers (IL-1β, IL-6, IL-7, IL-10, IL-12, IL-13, VEGF, FGF, GM-CSF, TNF-α, IFN-γ) of the condition. Surprisingly, the concentrations of most of the molecules (except for IL-6, IFN-γ, IP-10, VEGF) decreased when compared with the cells from the lean group. We postulate that the difference stemmed from the fact that in vivo cytokines were mostly secreted by the activated monocytes/macrophages and not adipocytes per se. This may also suggest that the aforementioned upregulated cytokines (IL-6, IFN-γ, IP-10, VEGF) might have been the ones that attracted monocytes and triggered the vicious cycle of tissue inflammation. Conclusions: Our study indicated that the adipocytes newly derived from the ADMSCs of obese patients with metabolic syndrome displayed a secretory fingerprint that may be characteristic to the early stages of the condition.
Patients receive lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 8 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Visits for research are done as part of the care, no visits are added. Two visits are planned for this group of patients : before and after initiation of therapy. These patients will be sampled twice with 51 mL of blood. Skin biopsies will be obtained from a subset of 30 patients to analyse the skin transcriptome, before and after treatment with anti-IL-23 biologics Data will be collected at the two timepoints.
Intracellular tau aggregation requires a local protein concentration increase, referred to as "droplets". However, the cellular mechanism for droplet formation is poorly understood. Here, we expressed OptoTau, a P301L mutant tau fused with CRY2olig, a light-sensitive protein that can form homo-oligomers. Under blue light exposure, OptoTau increased tau phosphorylation and was sequestered in aggresomes. Suppressing aggresome formation by nocodazole formed tau granular clusters in the cytoplasm. The granular clusters disappeared by discontinuing blue light exposure or 1,6-hexanediol treatment suggesting that intracellular tau droplet formation requires microtubule collapse. Expressing OptoTau-ΔN, a species of N-terminal cleaved tau observed in the Alzheimer's disease brain, formed 1,6-hexanediol and detergent-resistant tau clusters in the cytoplasm with blue light stimulation. These intracellular stable tau clusters acted as a seed for tau fibrils in vitro. These results suggest that tau droplet formation and N-terminal cleavage are necessary for neurofibrillary tangles formation in neurodegenerative diseases.